Heart-focused medical device maker Edwards Lifesciences (EW) reported a Non-GAAP EPS of $0.61 which missed by $0.01, revenue of $1.32B which missed by $10M. EW has revised their guidance for 2022. A number of fundamental analysts have cut their price targets. Not a good morning for EW shareholders this Friday.
More from Investing
We now have worries about the Fed raising rates while bonds are acting like the economy is going to slow dramatically.
Let's uncover the Alpha Architect Inflation and Deflation exchange-traded fund.
The shares have recently failed at the underside of the declining 200-day moving average line.
We have a price target for this infrastructure engineering software firm.
This is typical bear market action in which stock picking doesn't matter much, and macro considerations are driving the indexes -- still, I've got a pick.